Project Grant R43HL147757

The Medical College of Wisconsin, Inc. received a $147,486 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with completion targeted for March 31, 2029. This award funds research investigating the mechanosensitive mechanisms underlying premature calcification in bicuspid aortic valve (BAV) disease, the most prevalent congenital heart disease affecting approximately 2% of...

Federal Project Grant Award Summary Boston University Medical Campus received a $122,625 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) beginning June 1, 2025 and concluding May 31, 2027. The award funds research and development of novel small molecule therapeutics targeting oxidized sirtuin-1 (SIRT1) as a potential treatment for aortic aneurysms in Marfan Syndrome. The research deliverables...

This K23 career development award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) totaling $348,778 supports a five-year training and research initiative at Weill Medical College of Cornell University, beginning September 5, 2025 and concluding August 31, 2030. The award provides Dr. Nupoor Narula with advanced training in cardiac magnetic resonance (CMR) imaging and cardiovascular genetics to establish her as an...

Federal Project Grant Award Summary Baylor College of Medicine received a $240,000 Project Grant from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with completion targeted for July 31, 2027. This research project investigates the epigenetic mechanisms through which thoracic aortic aneurysm and dissection (TAAD)-associated single nucleotide polymorphisms (SNPs) contribute to disease susceptibility in...

Northwestern University received a $150,104 Project Grant awarded on September 30, 2025, from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to develop tissue engineered vascular grafts (TEVGs) resistant to calcification. The research will utilize matrix metalloprotease-degradable polyethylene glycol (MMP-PEG) hydrogels to coat decellularized aortas and investigate the role of vasa vasorum angiogenesis in improving TEVG...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2.36 million Project Grant to the Trustees of Boston University (Boston University Medical Campus) on May 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). This research grant, with a completion date of February 28, 2029, supports a four-year investigation into thiol redox signaling mechanisms in aortic aneurysm development associated with Marfan Syndrome. The research project...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a project grant of $165,488 under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of March 5, 2026 and completion deadline of December 31, 2028. This research project, titled "Defining the Role of TCF21 in Adventitial Fibroblasts in Atherosclerosis," focuses on understanding the molecular mechanisms underlying coronary artery...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $118,919 in Project Grant funding (CFDA 93.837: Cardiovascular Diseases Research) to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, effective August 1, 2025, through June 30, 2027. This research initiative focuses on advancing diagnostic and therapeutic understanding of fibromuscular dysplasia (FMD), a vascular disease predominantly affecting women. The primary...

This Project Grant award of $733,439 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports basic research investigating sexually dimorphic mechanisms in human thoracic aortic aneurysm (TAAD) formation. Awarded to the Regents of the University of Michigan on September 5, 2025, with a completion date of June 30, 2029, the research will deliver molecular and functional characterization of cells constituting human TAA...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel oral small molecule therapeutics for the treatment of progressive pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The goal is to create a safer and more effective therapy compared to the currently approved drugs, which only slow disease progression and have significant side effects. Novomedix will...